Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO

@tomleblancMD

Patient experience & cancer outcomes researcher | Leukemia & palliative care doc | Chief PX and Safety Officer @DukeCancer | Tweets are mine alone.

Durham, NC

Joined March 2012

2KFollowing

5KFollowers

Pinned

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO@tomleblancMD · Sep 19, 2019

I’m on #CapitolHill today discussing #palliative care, specifically the fact that blood #cancer patients are being put in a terrible position at end of life: being forced to choose between hospice and receiving #palliative blood transfusions #hpm #hapc (1/14)

222

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Conquer Cancer, the ASCO Foundation@ConquerCancerFd · Jul 24

This month, your donation to Conquer Cancer will go twice as far, thanks to a special $20,000 matching gift! Give today. brnw.ch/21wUob5 #ConquerCancer #DoubleYourImpact

1.0K

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Uri Manor 💔@manorlaboratory · Jul 6

My lab’s 5-year NIH R01 grant, awarded to study gene therapy for hearing loss, was abruptly terminated. I want to share how this action has been incredibly harmful and disruptive, not just to my lab, but to the scientific process itself. 1/15

156

2.0K

9.0K

1.0K

767.0K

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Fadi Haddad, MD@FadiHaddad_MD · Jul 5

📢 Out in @NEJMEvidence 👫N=1132 pts; age 18-60 🔹ND #AML 🔹Consolidation with IDAC vs HIDAC 🔹5-yr OS = 59% vs 58% 🔹Lower incidence of myelosuppressio & AEs with IDAC ➡️ IDAC non inferior to HIDAC #leusm @OncoAlert evidence.nejm.org/doi/pdf/10.105…

9.0K

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Neil deGrasse Tyson@neiltyson · Jun 16

Every machine in a Hospital that diagnoses your body without cutting you open is based on a principle of Physics, discovered by a Physicist who had no interest in Medicine. If you think the world doesn’t need Basic Science, or that somehow Science has failed you, think again.

393

2.0K

12.0K

397

416.0K

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

AML Hub@AML_Hub · Jun 15

CONGRESS | #EHA2025 | PRESENTATION @MusaYilmazMD @MDAndersonNews shares updated results from a phase I/II trial of decitabine (DAC), venetoclax (VEN), plus quizartinib in newly diagnosed (n = 30) and R/R (n = 46) FLT3-ITDm AML. DAC+VEN+quizartinib response rates were high in the…

2.0K

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Duke Hematologic Malignancies & Cellular Therapy@DukeHMCT · Jun 15

Real-world outcomes of TP53-mut #MPN are heterogeneous, with worse prognosis in accelerated/blast-phase disease, complex karyotype, and multi-hit #TP53, a U.S. #COMMAND consortium study featuring @DukeCancer faculty @ChenyuLinMD as a co-author. @BrJHaem onlinelibrary.wiley.com/doi/10.1111/bj…

201

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Talha Badar@TalhaBadarMD · Jun 15

#EHA2025 #EHA25 #ALL s/c blinatumomab for RR ALL, P1/1b data presented by Dr. Jabbour. 1. Given at 2 dose level, 250ug/500ug was better tolerated and selected for RP2D. 2. Responses were better compared to IV Blina. 3. Responses were seen among pts with prior IV blina exposed.

2.0K

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Leukemia Journal@LeukemiaJnl · Jun 19

Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL) | Leukemia nature.com/articles/s4137…

7.0K

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Talha Badar@TalhaBadarMD · Jun 13

#EHA2025 #youngEHA Great presentation by Dr. DiNardo, how to improve on VEN+HMA for intensive ineligible AML pts.. 1. Ven resistance mechanisms. 2. Novel targets 3. Ven triplets under development #leusm #AML #venetoclax_4_AML

115

8.0K

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

AML Hub@AML_Hub · Jun 12

CONGRESS | #EHA2025 | PRESENTATION Harry Erba @DukeCancer presents updated phase Ia/b results from the KOMET-007 trial, of ziftomenib RP2D (600 mg QD) combined with intensive induction chemotherapy (7+3), in newly diagnosed NPM1m or KMT2Ar AML. Ziftomenib was well tolerated, and…

867

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

AML Hub@AML_Hub · Jun 12

CONGRESS | #EHA2025 | PRESENTATION Gail Roboz @WeillCornell shares findings from phase IIb of the ASCERTAIN-V clinical trial (NCT04657081) of all-oral decitabine-cedazuridine (DEC-C) + venetoclax (VEN), in patients with newly diagnosed AML ineligible for intensive induction…

811

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Mikkael A. Sekeres MD, MS@MikkaelSekeres · Jun 10

Announcing the first EVER @JCO_ASCO Art of Oncology Narrative Medicine Contest! 🎉✍️🎗️🩺🎉 We're looking for essays that explore the human experience of cancer and reflect on the experience of trainees and early career hematologists/oncologists. Apply Now! ascopubs.org/jco/art-oncolo…

9.0K

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

calliecoombs@calliecoombsmd · Jun 12

This was an amazing effort and practice changing study for LGL leukemia - cyclophosphamide is superior to MTX with respect to ORR with comparable safety - took 10 years to accrue but shows can do RCT in rare hem diseases #EHA25 #EHA2025

155

15.0K

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Talha Badar@TalhaBadarMD · Jun 12

#EHA2025 #youngEHA Bleximenib with AZA+VEN for R/R and ND AML 👇🏽 presented by Dr. Andrew Wei #leusm #menin_inhibitors

5.0K

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Joshua Zeidner MD@LeukDocJZ · Jun 12

Impressive results of 7+3 + Ziftomenib in newly diagnosed AML patients with NPM1m or KMT2Ar presented by Harry Erba. We are embarking on a new era of menin inhibitors in combination with frontline therapy in newly Dx AML w/ NPM1m or KMT2Ar. @EHA_Hematology #EHA25

3.0K

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Duke Hematologic Malignancies & Cellular Therapy@DukeHMCT · Jun 12

An investigator-initiated clinical trial evaluating #Ruxolitinib and #Fostamatinib for steroid-refractory chronic #GVHD is now accruing at @DukeCancer, one of few combinatorial regimens being tested, based on work from #SarantopoulosLab. PIs @ChenyuLinMD @horwi001 #BMTsm…

352

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO@tomleblancMD · Jun 10

I'm delighted to partner with @ACCCBuzz on the development of educational content about acute myeloid leukemia (#AML). Take a look at our recent on-demand webinar, where we dive deeply into the how, what and why of bone marrow aspiration and biopsy: accc-cancer.org/home/learn/can……

516

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO@tomleblancMD · Jun 9

Unraveling the mysteries of molecular testing in AML….. 🕵️🧬🩸 for those interest in #AMLsm #LeuSM and #Hemepath Hope you find this video/podcast informative. w/ @Dr_AmerZeidan

SSpringer Health+ IME@SpringerIME · May 20

Explore practical strategies for integrating molecular testing into AML care - overcome barriers and apply insights to improve patient outcomes. Part of The AML Expert Series - listen now: bit.ly/AMLSeries_Ep1 #acutemyeloidleukemia #AML #AMLtreatment #MedEd

3.0K

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Fumiko Ladd Chino, MD, FASCO@fumikochino · Jun 9

🚨Deadline Alert TOMORROW‼️ 📅 Tuesday, June 10 #ASCOQLTY25 Abstract submissions are due this week! Share your solutions-driven research & help shape the future of quality cancer care. Don’t miss the premier forum for innovation in care delivery! 👉 asco.org/quality

6.0K

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Joshua Zeidner MD@LeukDocJZ · Jun 7

Thanks to @binaytara for hosting the first annual North Carolina Hematologic Malignancies Symposium in Durham chaired by Debbie Stephens @UNC_Lineberger. It was an honor to speak with all star lineup of speakers. education.binaytara.org/content/north-…

1.0K